vs
ABVC BIOPHARMA, INC.（ABVC）与AVAX ONE TECHNOLOGY LTD.（AVX）财务数据对比。点击上方公司名可切换其他公司
AVAX ONE TECHNOLOGY LTD.的季度营收约是ABVC BIOPHARMA, INC.的1.3倍（$1.0M vs $796.0K），ABVC BIOPHARMA, INC.净利率更高（-256.6% vs -1633.6%，领先1376.9%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
ABVC vs AVX — 直观对比
营收规模更大
AVX
是对方的1.3倍
$796.0K
净利率更高
ABVC
高出1376.9%
-1633.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $1.0M |
| 净利润 | $-2.0M | $-16.6M |
| 毛利率 | 100.0% | — |
| 营业利润率 | -246.8% | -1522.1% |
| 净利率 | -256.6% | -1633.6% |
| 营收同比 | 104.5% | — |
| 净利润同比 | -417.4% | -480.2% |
| 每股收益（稀释后） | $-0.09 | $32.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCAVX
| Q4 25 | — | $1.0M | ||
| Q3 25 | $796.0K | $525.9K | ||
| Q2 25 | — | $452.0K | ||
| Q1 25 | — | $344.4K | ||
| Q4 24 | $2.0K | — | ||
| Q3 24 | $389.3K | $0 | ||
| Q2 24 | $117.1K | $41.3K | ||
| Q1 24 | $1.2K | — |
净利润ABVCAVX
| Q4 25 | — | $-16.6M | ||
| Q3 25 | $-2.0M | $-8.4M | ||
| Q2 25 | — | $-8.1M | ||
| Q1 25 | — | $-145.5K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-394.8K | $-5.8M | ||
| Q2 24 | $-942.3K | $-4.2M | ||
| Q1 24 | $-2.8M | — |
毛利率ABVCAVX
| Q4 25 | — | — | ||
| Q3 25 | 100.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 22.9% | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | 18.4% | ||
| Q1 24 | 77.0% | — |
营业利润率ABVCAVX
| Q4 25 | — | -1522.1% | ||
| Q3 25 | -246.8% | -496.6% | ||
| Q2 25 | — | -328.4% | ||
| Q1 25 | — | -600.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -77.7% | — | ||
| Q2 24 | -734.2% | -2827.7% | ||
| Q1 24 | -235539.8% | — |
净利率ABVCAVX
| Q4 25 | — | -1633.6% | ||
| Q3 25 | -256.6% | -1588.0% | ||
| Q2 25 | — | -1783.4% | ||
| Q1 25 | — | -42.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -101.4% | — | ||
| Q2 24 | -804.4% | -10243.5% | ||
| Q1 24 | -235203.2% | — |
每股收益（稀释后）ABVCAVX
| Q4 25 | — | $32.17 | ||
| Q3 25 | $-0.09 | $-5.55 | ||
| Q2 25 | — | $-27.60 | ||
| Q1 25 | — | $-1.17 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.03 | $-57.19 | ||
| Q2 24 | $-0.08 | $-83.03 | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $22.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $187.0M |
| 总资产 | $21.2M | $195.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCAVX
| Q4 25 | — | $22.1M | ||
| Q3 25 | $257.2K | $894.7K | ||
| Q2 25 | — | $185.3K | ||
| Q1 25 | — | $1.4M | ||
| Q4 24 | $313.1K | — | ||
| Q3 24 | $208.2K | — | ||
| Q2 24 | $200.0K | — | ||
| Q1 24 | $106.4K | — |
总债务ABVCAVX
| Q4 25 | — | — | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | — | $8.6M | ||
| Q1 25 | — | $10.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | — |
股东权益ABVCAVX
| Q4 25 | — | $187.0M | ||
| Q3 25 | $12.1M | $12.2M | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | — | $6.4M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $1.6M | $6.7M | ||
| Q2 24 | $1.8M | $11.3M | ||
| Q1 24 | $1.7M | — |
总资产ABVCAVX
| Q4 25 | — | $195.0M | ||
| Q3 25 | $21.2M | $16.5M | ||
| Q2 25 | — | $15.2M | ||
| Q1 25 | — | $16.8M | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | $7.8M | $10.8M | ||
| Q2 24 | $8.0M | $15.7M | ||
| Q1 24 | $8.0M | — |
负债/权益比ABVCAVX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 2.11× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.28× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $-14.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABVCAVX
| Q4 25 | — | $-14.4M | ||
| Q3 25 | $-964.7K | $-2.4M | ||
| Q2 25 | — | $-884.1K | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $60.2K | $-1.2M | ||
| Q2 24 | $-211.4K | $-919.2K | ||
| Q1 24 | $-955.8K | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
